Elite in Sickle Cell Disease

Dr. Lakshmanan Krishnamurti

Hematology | Oncology
1405 Clifton Rd Ne, 
Atlanta, GA 
Accepting New Patients
Elite in Sickle Cell Disease
1405 Clifton Rd Ne, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lakshmanan Krishnamurti is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Krishnamurti is rated as an Elite provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Krishnamurti is currently accepting new patients.

His clinical research consists of co-authoring 117 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 104 articles and participated in 2 clinical trials in the study of Sickle Cell Disease.

Specialties
Hematology
Oncology
Licenses
Specialist in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

1405 Clifton Rd Ne, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Enrollment Status: Completed
Publish Date: December 14, 2023
Intervention Type: Genetic
Study Drug: BCL11A-Positive CD34-Positive Hematopoietic Stem Cells
Study Phase: Phase 1/Phase 2
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Enrollment Status: Terminated
Publish Date: September 29, 2023
Intervention Type: Biological, Drug
Study Drugs: Rivogenlecleucel, Rimiducid
Study Phase: Phase 1/Phase 2
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: November 26, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 2
Efficacy of a Decision Aid for Hydroxyurea(HU) in Sickle Cell Disease(SCD)
Efficacy of a Decision Aid for Hydroxyurea(HU) in Sickle Cell Disease(SCD)
Enrollment Status: Terminated
Publish Date: July 23, 2019
Intervention Type: Other
Study Phase: Not Applicable
View 4 Less Clinical Trials

117 Total Publications

Informed Shared Decision-Making or Rigid Eligibility and Exclusion Criteria for Gene Therapy for Sickle Cell Disease?
Informed Shared Decision-Making or Rigid Eligibility and Exclusion Criteria for Gene Therapy for Sickle Cell Disease?
Journal: Blood advances
Published: April 29, 2025
Similar Doctors
Distinguished in Sickle Cell Disease
Dr. Douglas C. Collins
Oncology
Distinguished in Sickle Cell Disease
Dr. Douglas C. Collins
Oncology

Metro Hematology Oncology Center

320 Parkway Drive Northeast, Ste232, 
Atlanta, GA 
 (4.7 miles away)
404-522-0917
Experience:
48+ years
Languages Spoken:
English
See accepted insurances

Douglas Collins is an Oncologist in Atlanta, Georgia. Dr. Collins has been practicing medicine for over 48 years and is rated as an Advanced provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Sickle Cell Disease, Non-Hodgkin Lymphoma, Inflammatory Breast Cancer, Schnitzler Syndrome, and Bone Marrow Aspiration.

Distinguished in Sickle Cell Disease
Dr. Fuad E. El Rassi
Hematology Oncology | Hematology | Oncology
Distinguished in Sickle Cell Disease
Dr. Fuad E. El Rassi
Hematology Oncology | Hematology | Oncology

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (0.1 miles away)
404-778-7525
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Fuad El Rassi is a Hematologist Oncology specialist and a Hematologist in Atlanta, Georgia. Dr. El Rassi is rated as a Distinguished provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobin C Disease, Hemoglobinopathy, and Hemoglobin E Disease. Dr. El Rassi is currently accepting new patients.

Distinguished in Sickle Cell Disease
Dr. Sreekanth Reddy
Oncology | Hematology Oncology | Hematology
Distinguished in Sickle Cell Disease
Dr. Sreekanth Reddy
Oncology | Hematology Oncology | Hematology

American Oncology Partners PA

6985 Mcginnis Ferry Rd, Suite 100, 
Johns Creek, GA 
 (20.7 miles away)
678-726-6203
Languages Spoken:
English
See accepted insurances

Sreekanth Reddy is an Oncologist and a Hematologist Oncology provider in Johns Creek, Georgia. Dr. Reddy is rated as a Distinguished provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Non-Hodgkin Lymphoma, Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krishnamurti's expertise for a condition
ConditionClose
    View All 17 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile